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Introduction: Acute rejection (AR) and delayed graft function 
(DGF) are 2 main adverse early posttransplant events that one 
would like to avoid. DGF conventionally defined as requirement 
for dialysis during the first postperative week is a form of acute 
renal failure that results in posttransplant oligouria, increases risk of 
AR, and decreases graft survival. Higher incidence of DGF in renal 
transplant recipients treated by CsA was described previously, but 
the mechanism of this effect has not been explained yet. The aim 
of this study was to compare blood concentrations of CsA and its 
metabolites AM1, AM9, and AM4N in patients with immediate and 
DGF renal function.
Patients (or Materials) and Methods: Fourteen adult renal transplant 
recipients (8 males) were prospectively observed during the first 3 
months. The therapy was based on CsA microemulsion (Sandimun 
Neoral® or Equoral®) in combination with mycophenolate and 
prednisone and was adapted in accordance with guidelines and clini-
cal outcomes. First dose of CsA (4–8 mg/kg) was administered in 
the day of transplantation. On the basis of clinical status confirmed 
by serum creatinine level and creatinine clearance the subjects were 
divided in to 2 groups with immediate graft function (IF-7 patients) 
and with DGF (7 patients). The CsA and the metabolites C0, C2, and 
C4 concentrations were analyzed using LC-MS/MS method in days 
1 to 7, 14, 21, and 28.1
Results: Significant higher creatinine levels and significant lower 
creatinine clearance were found in DGF group (P < 0.05). During 
the first month the CsA C0 were significantly higher (237 [127] 
μ g/L vs 170 [72] μ g/L; P = 0.0002) while C2 and AUC0-4 were 
lower (698 [320] μ g/L vs 919 [412] μ g/L, 2162 [830] μ g*h/L vs 
2610 [1002] μ g*h/L; P < 0.01). The highest concentrations dif-
ferences were found in AM4N metabolite: C0 (66.5 [61] μ g/L vs 
7.5 [7.4] μ g/L), C2 (111 [93] ug/L vs 41 [34] ug/L), C4 (134 [131] 
μ g/L vs 32 [22] ug/L), AUC0–4 (415 [352] μ g*h/L vs 121 [91] 
μ g*h/L). AM4N/CsA ratio: C0 (0.3 [0.28] vs 0.05 [0.04]), C2 (0.19 
[0.17] vs 0.05 [0.04]), C4 (0.25 [0.25] vs 0.06 [0.04]). All results 
were significant for P < 0.0001. Similarly C0, C2, C4, AUC0–4 of 
AM1 and AM1/CsA ratio were significantly lower in DGF group 
(P < 0.001). The graft function in DGF group recovered between 
1 week and 2 months and the differences of CsA and metabolites 
concentrations disappeared.
Conclusion: Metabolismus of CsA in patients with IF and DGF was 
different. Higher concentrations of AM4N and AM1 should be cause 
or markers.Therefore, TDM of CsA in combination with fenotypiza-
tion is recommended.
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Introduction: Streptomycin, as other aminoglycosides, exhibits 
concentration-dependent bacterial killing but has a narrow thera-
peutic window. It is primarily eliminated unchanged by the kidneys. 
Data and dosing information to achieve a safe regimen in patients 
with chronic renal failure undergoing hemodialysis (HD) are scarce. 
Although main adverse reactions are related to prolonged, elevated 
serum concentrations, literature recommendation is to administer 
streptomycin after each HD.
Patients (or Materials) and Methods: We report the case of a patient 
with end-stage renal failure, undergoing HD, who was successfully 
treated with streptomycin for gentamicin-resistant Enterococcus 
faecalis bacteremia with prosthetic arteriovenous fistula infection. 
Streptomycin was administered intravenously 7.5 mg/kg, 3 hours 
before each dialysis (3 times a week) during 6 weeks in combination 
with amoxicillin. Streptomycin plasma levels were monitored with 
repeated blood sampling before, after, and between HD sessions. A 
2-compartment model was used to reconstruct the concentration time 
profile over days on and off HD.
Results: Streptomycin trough plasma-concentration was 2.8 mg/L. 
It peaked to 21.4 mg/L 30 minutes after intravenous administration, 
decreased to 18.2 mg/L immediately before HD, and dropped to 4.5 
mg/L at the end of a 4-hour HD session. Plasma level increased again 
to 5.7 mg/L 2 hours after the end of HD and was 2.8 mg/L 48 hours 
later, before the next administration and HD. The pharmacokinetics 
of streptomycin was best described with a 2-compartment model. 
The computer simulation fitted fairly well to the observed concentra-
tions during or between HD sessions. Redistribution between the 2 
compartments after the end of HD reproduced the rebound of plasma 
concentrations after HD. No significant toxicity was observed during 
treatment. The outcome of the infection was favorable, and no sign 
of relapse was observed after a follow-up of 3 months.
Conclusion: Streptomycin administration of 7.5 mg/kg 3 hours 
before HD sessions in a patient with end-stage renal failure resulted 
in an effective and safe dosing regimen. Monitoring plasma levels 
along with pharmacokinetic simulation document the suitability of 
this dosing scheme, which should replace current dosage recommen-
dations for streptomycin in HD.
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Introduction: Mammalian hibernation is characterized by profound 
reductions in metabolism and body temperature. As a result, hibernat-
ing animals enter a state of suspended animation called “torpor,” where 
